OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

NEW YORK (TheStreet) -- OXiGENE (OXGN) shares are up 6.94% to $1.54 in afternoon trading on Monday after the cancer treatment developer announced that the FDA gave positive feedback for the proposed phase 3 study of its platinum-resistant ovarian cancer treatment candidate, fosbretabulin.

"We are extremely pleased by the agency's support for advancing to a Phase 3 trial and their guidance in defining a registration pathway for fosbretabulin in platinum-resistant ovarian cancer," said CEO Bill Schwieterman, M.D.

The FDA agreed with the company that the trials should focus on fosbretabulin in conjunction with bevacizumab directly against a chemotherapy treated control group with progression-free survival as the primary endpoint of the trial.

The company said that it plans to submit an application to the FDA for a Special Protocol Assessment (SPA) later this year. An SPA is a declaration by the regulatory agency that a yet to be completed phase 3 drug trial's design and clinical endpoints are acceptable for approval.

OXGN Chart OXGN data by YCharts

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists